- Short Report
- Open Access
SR proteins and the nonsense-mediated decay mechanism are involved in human GLB1 gene alternative splicing
© Grinberg et al; licensee BioMed Central Ltd. 2008
Received: 31 October 2008
Accepted: 29 December 2008
Published: 29 December 2008
The human GLB1 gene is known to give rise to two alternatively spliced mRNAs, which encode two different proteins: lysosomal β-galactosidase (β-gal) and elastin-binding protein (EBP). The β-gal transcript includes the 16 exons of the GLB1 gene. In the EBP transcript, exons 3, 4 and 6 are skipped, while exon 5 has a different reading frame. However, little is known on how this alternative splicing is regulated.
Cycloheximide treatment of HeLa cells and human fibroblasts revealed the presence of new transcripts that are otherwise degraded by nonsense-mediated decay (NMD). A minigene carrying the exons involved in the alternative splicing of GLB1 was constructed. Improving the acceptor-site scores of exons 3 or 4 increased the relative inclusion of these exons, but did not stop them being skipped in some transcripts. Overexpression of different SR proteins altered the relative proportion of the different transcripts produced by the minigene, indicating a possible mechanism for the regulation of the alternative splicing of GLB1. Finally, a comparison of this gene among different species was performed.
In the processing of the GLB1 RNA several transcripts are generated, but only those with a correct reading frame are not degraded. The differential inclusion/exclusion of exons could be partially explained by the relatively weak splice sites in the exons involved. Different SR proteins have an effect on the process of skipping of these exons, at least in the minigene conditions, indicating a possible mechanism for the regulation of the alternative splicing of the GLB1 gene.
The existence of splicing in eukaryotic RNAs has been known for more than 25 years [1, 2]. Aternative splicing, which may affect 30 to 70% of the genes in higher eukaryotes [3, 4], allows the generation of multiple transcripts by different mechanisms such as exon skipping/inclusion, alternative 5' or 3' splice sites, intron retention or mutually exclusive exons. Alternative exons often have suboptimal splice sites and/or suboptimal length when compared with constitutive exons. Besides the proteins that are present in constitutive splicing, a group of proteins that bind to pre-mRNA sequences are also necessary in alternative splicing . The sequences where these proteins bind are called exonic or intronic enhancers (ESEs or ISEs) and silencers (ESSs or ISSs). Most of the ESEs are recognized by SR proteins. They constitute a family of proteins that has an RS domain (rich in arginines and serines) and 1 or 2 RRM domains (RNA-binding domains) and are essential, multifunctional splicing factors required both for spliceosome assembly and for alternative splicing . On the other hand, the best characterized ESSs and ISSs are recognized by members of the heterogeneous nuclear ribonucleoprotein (hnRNP) family, which are highly abundant RNA-binding proteins that lack an RS domain . It is known that these proteins have a dose-dependent effect and that the binding of SR and hnRNP proteins on the pre-mRNA allows the splicing machinery to act in a tissue or in a developmental stage specific manner .
Nonsense-mediated mRNA decay (NMD) is a well known mechanism that degrades mRNAs harbouring premature termination codons (PTCs), not only generated by de novo nonsense mutations but also of those naturally found in physiological transcripts . Over recent years, the coupling between NMD and alternative splicing has become more evident .
The GLB1 gene (GenBank NM_000404.1), located on chromosome 3 at 3p21.33 and organized into 16 exons, is the gene coding for the β-galactosidase protein (E.C.184.108.40.206) . This enzyme cleaves terminal β-galactoses from different substrates in the lysosome. A second transcript generated by alternative splicing was described , but it was not until 10 years later that the protein coded by this second transcript, the elastin-binding protein (EBP), was identified . While the β-galactosidase cDNA is 2.5 kb long, the second transcript is only 2 kb, lacks exons 3, 4 and 6, and bears exon 5 in a different reading frame. The amount of the 2-kb transcript was also reported to be much lower (less than 1/10) than that of the 2.5-kb transcript .
Mutations in the GLB1 gene that result in the absence or reduced activity of the lysosomal enzyme β-galactosidase produce two different diseases: GM1-gangliosidosis (MIM# 230500) and Morquio B (MIM# 253010). A role of EBP in these diseases has also been suggested but is still under discussion [14, 15].
Efforts have been made to establish the function and interactions of both proteins. In contrast, no studies have been reported on the way alternative splicing of the GLB1 gene is regulated. Here we present an attempt to establish the mechanisms underlying this alternative splicing.
Vector construction, cell culture and transfection conditions, and molecular biology techniques are provided [see Additional file 1].
Endogenous transcript analysis
Primers and RT-PCR conditions
Primers employed in the RT-PCR
Pairs of primers employed
Minigene transcript analysis
To determine whether some of the missing intronic sequences were essential for the correct splicing of any of the cloned exons, the BX construct was transfected in HeLa cells and RT-PCR was carried out using plasmid-specific primers (T7/SP6). A single band was obtained (data not shown). Sequencing of this PCR product showed that it corresponded to a transcript that included the 6 cloned exons, indicating that the intron regions present in the BX construct bore the necessary cis sequences for correct splicing. If alternative splicing giving rise to the EBP transcript was taking place, it was at a very low level (as in the endogenous splicing), since no band corresponding to this transcript was detected.
Effect of exon 3 and exon 4 acceptor sites on alternative splicing
In silico analysis of the 3' splice sites (3'ss) of the GLB1 gene revealed a low score of 2.5 for the site flanking exon 4, a relatively low score of 6 for the site adjacent to exon 3 and a high score of 10 for exon 6 acceptor site, compared to the average score of constitutive exons (7.9). To check whether the skipping of exons 3 and 4 in the alternative splicing was due to the weak acceptor sites, 2 positions on each 3'ss were mutagenized in the BX minigene, generating the BX3 and BX4 constructs. These changes increased the 3'ss scores on exons 3 and 4, from 6 to 9.5 and from 2.5 to 7, respectively (Figure 2a, b). Analysis of the transcripts generated by these plasmids showed an increase of the transcript including only exon 3 (BX3 lane) and of the transcript including only exon 4 (BX4 lane), although the transcripts lacking both exons were also observed (Figure 3a). Quantification of the transcripts bearing exon 3 (or exon 4) versus transcripts lacking exon 3 (or exon 4), showed small but significant increases. As expected, plasmid BX3 produced proportionally more transcripts bearing exon 3 than BX (116%, Figure 3b), and plasmid BX4 produced more bearing exon 4 (120%, Figure 3c). It should be noted that plasmid BX4 also produced more transcripts bearing exon 3 than BX (124%), but this was not significant. Nevertheless, the fact that some transcripts with skipped exons 3 and/or 4 were still produced, suggests that the weak 3' splice sites are not sufficient to explain why these exons might be skipped.
Effect of over-expression of SR proteins on alternative splicing
The differences in the pattern observed for each protein may indicate their different roles in the constitutive and alternative splicing of these exons. However, it should be taken into account that the over-expression of the SR proteins in the minigene experiments, which is far from being a physiological situation, could alter the interactions between the over-expressed and endogenous SR proteins. Moreover, the characteristics of the minigene, such as the type of promoter or the lack of some of the intronic sequences, should also be considered.
GLB1 alternative splicing in other species
It had already been described that the EBP could not be generated in mouse (Mus musculus) through the alternative splicing of the GLB1 gene, because the translation of exon 5 in mouse is only possible in the reading frame that codes for lysosomal β-galactosidase . Analysis of the GLB1 exon 5 sequences in different species showed that this also happens in rat (Rattus norvegicus). However, in other mammals such as dog (Canis familiaris), cat (Felis catus), crab-eating macaque (Macaca fascicularis) or rabbit (Oryctolagus cuniculus) and also in birds such as the chicken (Gallus gallus), both reading frames are possible. Therefore, in all the species analyzed in silico, except for rat and mouse, a reading frame where exons 3, 4 and 6 are skipped is possible.
To see if the EBP alternative splicing (i.e. exclusion of exons 3, 4 and 6) occurred in mice, RAW264.7 cells were cultured in the presence and absence of CHX, and β-Gal- and EBP-like-specific RT-PCR were carried out. The C1Fm/C1Rm primers were used for β-Gal and the C1Fm/EBPRm primers for EBP-like (Table 1). The EBP-like transcript was detected only in the CHX-treated cells (data not shown).
The existence of this EBP-like transcript suggests that its absence in rodents (Murinae) could be explained by the presence of the PTC (a change that is synonymous in the β-gal frame) and the corresponding degradation by NMD. The question of which is the gene coding for the mouse EBP protein, if it exists, or which protein performs a similar function, remains open.
We would like to thank Alberto R. Kornblihtt and Matias Blaustein for advice, for critical reading of the MS and for providing the SR plasmids. We also thank Amparo Chabás for her permanent support to our research on lysosomal diseases. We are also grateful to Mónica Cozar for technical support and to Robin Rycroft for revising the English. RS was the recipient of a fellowship from the Spanish Ministerio de Educación y Cultura. Financial support was provided by CICYT (SAF2006-12276), AGAUR (2005SGR00848) and CIBERER (INTRA/07/720.1). The CIBER de Enfermedades Raras is an initiative of the ISCIII.
- Berget SM, Moore C, Sharp PA: Spliced segments at the 5' terminus of adenovirus 2 late mRNA. Proc Natl Acad Sci USA. 1977, 74 (8): 3171-3175. 10.1073/pnas.74.8.3171.PubMed CentralView ArticlePubMedGoogle Scholar
- Chow LT, Gelinas RE, Broker TR, Roberts RJ: An amazing sequence arrangement at the 5' ends of adenovirus 2 messenger RNA. Cell. 1977, 12 (1): 1-8. 10.1016/0092-8674(77)90180-5.View ArticlePubMedGoogle Scholar
- Modrek B, Lee C: A genomic view of alternative splicing. Nat Genet. 2002, 30 (1): 13-19. 10.1038/ng0102-13.View ArticlePubMedGoogle Scholar
- Roberts GC, Smith CW: Alternative splicing: combinatorial output from the genome. Curr Opin Chem Biol. 2002, 6 (3): 375-383. 10.1016/S1367-5931(02)00320-4.View ArticlePubMedGoogle Scholar
- Cartegni L, Chew SL, Krainer AR: Listening to silence and understanding nonsense: exonic mutations that affect splicing. Nat Rev Genet. 2002, 3 (4): 285-298. 10.1038/nrg775.View ArticlePubMedGoogle Scholar
- Graveley BR: Sorting out the complexity of SR protein functions. Rna. 2000, 6 (9): 1197-1211. 10.1017/S1355838200000960.PubMed CentralView ArticlePubMedGoogle Scholar
- Zhu J, Mayeda A, Krainer AR: Exon identity established through differential antagonism between exonic splicing silencer-bound hnRNP A1 and enhancer-bound SR proteins. Mol Cell. 2001, 8 (6): 1351-1361. 10.1016/S1097-2765(01)00409-9.View ArticlePubMedGoogle Scholar
- Caceres JF, Kornblihtt AR: Alternative splicing: multiple control mechanisms and involvement in human disease. Trends Genet. 2002, 18 (4): 186-193. 10.1016/S0168-9525(01)02626-9.View ArticlePubMedGoogle Scholar
- Mendell JT, Sharifi NA, Meyers JL, Martinez-Murillo F, Dietz HC: Nonsense surveillance regulates expression of diverse classes of mammalian transcripts and mutes genomic noise. Nat Genet. 2004, 36 (10): 1073-1078. 10.1038/ng1429.View ArticlePubMedGoogle Scholar
- Lewis BP, Green RE, Brenner SE: Evidence for the widespread coupling of alternative splicing and nonsense-mediated mRNA decay in humans. Proc Natl Acad Sci USA. 2003, 100 (1): 189-192. 10.1073/pnas.0136770100.PubMed CentralView ArticlePubMedGoogle Scholar
- Oshima A, Itoh K, Nagao Y, Sakuraba H, Suzuki Y: Beta-galactosidase-deficient human fibroblasts: uptake and processing of the exogenous precursor enzyme expressed by stable transformant COS cells. Hum Genet. 1990, 85 (5): 505-508. 10.1007/BF00194225.View ArticlePubMedGoogle Scholar
- Morreau H, Galjart NJ, Gillemans N, Willemsen R, Horst van der GT, d'Azzo A: Alternative splicing of beta-galactosidase mRNA generates the classic lysosomal enzyme and a beta-galactosidase-related protein. J Biol Chem. 1989, 264 (34): 20655-20663.PubMedGoogle Scholar
- Privitera S, Prody CA, Callahan JW, Hinek A: The 67-kDa enzymatically inactive alternatively spliced variant of beta-galactosidase is identical to the elastin/laminin-binding protein. J Biol Chem. 1998, 273 (11): 6319-6326. 10.1074/jbc.273.11.6319.View ArticlePubMedGoogle Scholar
- Caciotti A, Donati MA, Boneh A, d'Azzo A, Federico A, Parini R, Antuzzi D, Bardelli T, Nosi D, Kimonis V, et al: Role of beta-galactosidase and elastin binding protein in lysosomal and nonlysosomal complexes of patients with GM1-gangliosidosis. Hum Mutat. 2005, 25 (3): 285-292. 10.1002/humu.20147.View ArticlePubMedGoogle Scholar
- Morrone A, Bardelli T, Donati MA, Giorgi M, Di Rocco M, Gatti R, Parini R, Ricci R, Taddeucci G, D'Azzo A, et al: beta-galactosidase gene mutations affecting the lysosomal enzyme and the elastin-binding protein in GM1-gangliosidosis patients with cardiac involvement. Hum Mutat. 2000, 15 (4): 354-366. 10.1002/(SICI)1098-1004(200004)15:4<354::AID-HUMU8>3.0.CO;2-L.View ArticlePubMedGoogle Scholar
- Martinez-Contreras R, Fisette JF, Nasim FU, Madden R, Cordeau M, Chabot B: Intronic binding sites for hnRNP A/B and hnRNP F/H proteins stimulate pre-mRNA splicing. PLoS Biol. 2006, 4 (2): e21-10.1371/journal.pbio.0040021.PubMed CentralView ArticlePubMedGoogle Scholar
- Cavaloc Y, Bourgeois CF, Kister L, Stevenin J: The splicing factors 9G8 and SRp20 transactivate splicing through different and specific enhancers. Rna. 1999, 5 (3): 468-483. 10.1017/S1355838299981967.PubMed CentralView ArticlePubMedGoogle Scholar
- Lynch KW, Maniatis T: Assembly of specific SR protein complexes on distinct regulatory elements of the Drosophila doublesex splicing enhancer. Genes Dev. 1996, 10 (16): 2089-2101. 10.1101/gad.10.16.2089.View ArticlePubMedGoogle Scholar
- Morreau H, Bonten E, Zhou XY, D'Azzo A: Organization of the gene encoding human lysosomal beta-galactosidase. DNA Cell Biol. 1991, 10 (7): 495-504.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.